# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters a...
Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management...
bluebird bio (NASDAQ:BLUE) reported quarterly sales of $18.600 million which missed the analyst consensus estimate of $19.551 m...
bluebird bio, Inc. (NASDAQ:BLUE) today announced that it received a notice (the "notice") on April 24, 2024 from The Na...
- SEC Filing
RBC Capital analyst Luca Issi reiterates bluebird bio (NASDAQ:BLUE) with a Sector Perform and maintains $6 price target.